Table 2.
Anthropometric and clinical characteristics of the 2.5-year and validation cohorts and the baseline characteristics of the participants who completed and were lost to follow-up at 2.5-year follow-up.
| Baseline, completed 2.5-year (Number (%) unless stated otherwise) (n = 1,401) | Baseline, not completed 2.5-year (Number (%) unless stated otherwise) (n = 1,065) | 2.5-year (Number (%) unless stated otherwise) (n = 1,401) | Validation (Number (%) unless stated otherwise) (n = 573) | |
|---|---|---|---|---|
| ANTHROPOMETRIC AND CLINICAL | ||||
| Body Mass Index | ||||
| Underweight (<18.5) | 71 (5.1) | 35 (3.4) | 60 (4.3) | 31 (5.4) |
| Normal (18.5–<25) | 792 (56.6) | 501 (48.1) | 781 (55.8) | 299 (52.2) |
| Overweight (25 – <30) | 304 (21.7) | 252 (24.2) | 304 (21.7) | 126 (22.0) |
| Obese (≥30) | 232 (16.6) | 253 (24.3) ∧ | 254 (18.2) | 107 (18.7) |
| (Missing) | (2 (0.1)) | (24 (2.3) ∧ ) | (2 (0.1)) | (10 (1.75)) |
| NUMBER OF COMORBIDITIES | ||||
| 0 | 516 (36.8) | 340 (31.9) | 715 (51.0) | 321 (56.0) |
| 1 | 392 (28.0) | 232 (21.8) | 366 (26.1) | 131 (22.9) |
| 2 | 270 (19.3) | 216 (20.3) | 182 (13.0) | 61 (10.7) |
| ≥3 | 223 (15.9) | 277 (26.0) ∧ | 138 (9.9) | 60 (10.5) |
| CURRENTLY USE A DISEASE MODIFYING DRUG? | ||||
| No | 747 (53.3) | 574 (53.9) | 812 (58.0) | 310 (54.1) |
| Yes | 654 (46.7) | 491 (46.10) | 589 (42.0) | 263 (45.9) |
| DISABILITY LEVEL (PATIENT-DETERMINED DISEASE STEPS) | ||||
| Normal/mild | 787 (56.2) | 476 (44.7) | 783 (55.9) | 343 (59.9) |
| Moderate | 442 (31.6) | 353 (33.2) ∧ | 400 (28.6) | 169 (29.5) |
| Severe | 117 (8.4) | 123 (11.6) ∧ | 177 (12.6) | 48 (8.4) |
| (Missing) | (55 (3.93)) | (113 (10.6) ∧) | (41 (2.9)) | (13 (2.3)) |
| Mental Health Composite Quality Of Life (MSQOL-54) * | 70.3 (19.6) | 61.6 (22.7) | 70.3 (20.4) | 68.9 (20.6) |
| (Missing, n (%)) | (74 (5.3)) | (122 (11.5) ∧) | 85 (6.07) | (46 (8.0)) |
| Physical Health Composite Quality Of Life (MSQOL-54) * | 63.4 (32.3) | 54.6 (33.8) | 60.9 (30.4) | 65.1 (32.8) |
| (Missing, n (%)) | (42 (3.0)) | (68 (6.4) ∧) | 43 (3.07) | (12 (2.1)) |
| DEPRESSION RISK (PATIENT HEALTH QUESTIONNAIRE−9 SCORE) | ||||
| 0 – 4: no depression | - | - | 607 (48.0) | 245 (42.8) |
| 5–9: minimal depression symptoms | 383 (30.3) | 134 (23.4) | ||
| 10–14: likely major depression, mild | 144 (11.4) | 81 (14.1) | ||
| 15–19: likely major depression, moderate | 93 (7.4) | 26 (4.5) | ||
| ≥20: likely major depression, severe | 37 (2.9) | 21 (3.7) | ||
| (Missing) | (137 (9.8)) | (66 (11.5)) | ||
| DEPRESSION RISK (PATIENT HEALTH QUESTIONNAIRE−2 SCORE) | ||||
| 0–2: negative | 1139 (81.3) | 660 (62.0) | 1119 (79.9) | 441 (77.0) |
| ≥3: positive | 181 (12.9) | 244 (23.0) ∧ | 190 (13.6) | 82 (14.3) |
| (Missing) | (81(5.8)) | (161 (15.1) ∧) | (92(6.6)) | (50 (8.7)) |
| FATIGUE, AS DEFINED BY FATIGUE SEVERITY SCALE >35 | ||||
| No fatigue | 484 (34.6) | 251 (23.6) | 476 (37.5) | 201 (35.1) |
| Fatigue | 784 (56.0) | 619 (58.1) | 792 (62.5) | 308 (53.8) |
| (Missing) | (133 (9.5)) | (195 (18.3)) | (133 (9.5)) | (64 (11.2)) |
| Pearlin Mastery Scale** | - | - | 21 (19-25) | 21 (18-24) |
| (Missing) | (146 (10.4)) | (71 (12.4)) | ||
| PERFORMANCE SCALE—VISION COMPONENT (PS-V) | ||||
| Normal | 603 (43.0) | 225 (39.3) | ||
| Minimal | 430 (30.7) | 156 (27.2) | ||
| Mild | 201 (14.4) | 95 (16.6) | ||
| Moderate | 57 (4.1) | 23 (4.0) | ||
| Severe | 11 (0.8) | 10 (1.8) | ||
| Total | 1 (0.1) | 1 (0.2) | ||
| (Missing) | (98 (7.0)) | (63 (11.0)) | ||
*
Mean (standard deviation).
**
Median (25–75th percentile).
The baseline characteristics that are associated with missingness at 2.5-year follow-up are highlighted in gray with ∧ indicating the variables that are associated with higher odds of missingness at 2.5-year follow-up. For categorical variables, the reference category was taken as the first presented category in the table, and an arbitrary p-value cut-off of 0.05 was used.